Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J Supports ‘Spirit’ Of DTC Pricing Transparency, But Prefers PhRMA’s Voluntary Approach

Oct 16 2018

• By Joseph Haas

Related Content

Trump Administration's Rx-Price-Disclosure Reg Sets Up Legal Fight With PhRMA

Oct 16 2018

Industry Makes A Drug Price Transparency Push In DTC Ads, But Is It Too Little Too Late?

Oct 15 2018

Pharma Q3 Results Preview: J&J, Novartis & Roche

Oct 12 2018

J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says

Sep 13 2018

Related Companies

Johnson & Johnson

Additional Topics

Pricing Debate Commercial Policy Business Strategies BioPharmaceutical

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.